531 XNAS Volume
XNAS 25 Mar, 2025 9:50 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Maria Koehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Richard Wooster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Owen P. Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| David P. Bonita | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Otello Stampacchia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Caroline Germa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 579,100 | 579,100 | - | - | Stock Option (Right to Buy) | |
| Manfredi Mark | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 320,000 | 320,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey Ecsedy | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Marango Jotin | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 181,000 | 181,000 | - | - | Stock Option (Right to Buy) | |
| Maria Koehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Otello Stampacchia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| David P. Bonita | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Owen Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Richard Wooster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Sergio L. Santillana | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Jotin Marango | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Mark Manfredi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 220,000 | 220,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey Ecsedy | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Owen Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 35,040 | 35,040 | - | - | Stock Option (Right to Buy) | |
| David P. Bonita | Director | Purchase of securities on an exchange or from another person at price $ 3.71 per share. | 22 Jun 2022 | 23,419 | 1,936,097 | - | 3.7 | 86,884 | Common Stock |
| David P. Bonita | Director | Purchase of securities on an exchange or from another person at price $ 3.55 per share. | 22 Jun 2022 | 66,806 | 1,912,678 | - | 3.5 | 237,161 | Common Stock |
| David P. Bonita | Director | Purchase of securities on an exchange or from another person at price $ 4.37 per share. | 22 Jun 2022 | 65,965 | 2,002,062 | - | 4.4 | 288,267 | Common Stock |
| David P. Bonita | Director | Purchase of securities on an exchange or from another person at price $ 5.37 per share. | 22 Jun 2022 | 96,035 | 2,098,097 | - | 5.4 | 515,708 | Common Stock |
| Maria Koehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Richard Wooster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| David P. Bonita | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Otello Stampacchia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Jotin Marango | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 397,199 | 397,199 | - | - | Stock Option (Right to Buy) | |
| Mark Manfredi | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 238,900 | 238,900 | - | - | Stock Option (Right to Buy) | |
| Jeffrey Ecsedy | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 59,360 | 59,360 | - | - | Stock Option (Right to Buy) | |
| Sergio L. Santillana | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 70,400 | 70,400 | - | - | Stock Option (Right to Buy) | |
| Maude Tessier | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Richard Wooster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 29,200 | 29,200 | - | - | Stock Option (Right to Buy) | |
| Maude Tessier | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.51 per share. | 18 Jan 2022 | 8,265 | 100,578 | - | 4.5 | 37,275 | Common Stock |
| Maude Tessier | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.15 per share. | 18 Jan 2022 | 24,606 | 92,313 | - | 4.2 | 102,115 | Common Stock |
| Maude Tessier | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 8,265 | 28,963 | - | - | Stock Option (Right to Buy) | |
| Maude Tessier | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 24,606 | 11,186 | - | - | Stock Option (Right to Buy) | |
| Maude Tessier | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 38,915 | 5,560 | - | - | Stock Option (Right to Buy) | |
| Maude Tessier | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 18 Jan 2022 | 38,915 | 67,707 | - | 2.9 | 114,410 | Common Stock |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.14 per share. | 10 Jan 2022 | 36 | 44,511 | - | 2.1 | 77 | Common Stock |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 10 Jan 2022 | 36 | 44,475 | - | 12 | 432 | Common Stock |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 964 | 24,473 | - | - | Stock Option (Right to Buy) | |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jan 2022 | 36 | 25,437 | - | - | Stock Option (Right to Buy) | |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 10 Jan 2022 | 964 | 44,475 | - | 12 | 11,568 | Common Stock |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.15 per share. | 10 Jan 2022 | 964 | 45,439 | - | 2.1 | 2,069 | Common Stock |
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Maria Koehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 23,419 | 23,419 | - | - | Stock Option (Right to Buy) | |
| David P. Bonita | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Otello Stampacchia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.76 per share. | 10 Dec 2021 | 1,000 | 44,475 | - | 14.8 | 14,760 | Common Stock |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 1,000 | 25,473 | - | - | Stock Option (Right to Buy) | |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.15 per share. | 10 Dec 2021 | 1,000 | 45,475 | - | 2.1 | 2,146 | Common Stock |
| Xiaoyan Michelle Zhang | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2021 | 176,699 | 176,699 | - | - | Stock Option (Right to Buy) | |
| Maria Koehler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 26,838 | 26,838 | - | - | Stock Option (Right to Buy) | |
| Jean-Francois Formela | Director | 30 Mar 2021 | 11,258,117 | 0 | - | - | Series A-1 Preferred Stock | ||
| Jean-Francois Formela | Director | 30 Mar 2021 | 9,499,999 | 0 | - | - | Series A Preferred Stock | ||
| Jean-Francois Formela | Director | 30 Mar 2021 | 7,863,094 | 0 | - | - | Series A-2 Preferred Stock | ||
| Jean-Francois Formela | Director | 30 Mar 2021 | 5,362,888 | 0 | - | - | Series B Preferred Stock | ||
| Jean-Francois Formela | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 30 Mar 2021 | 125,000 | 874,634 | - | 16 | 2,000,000 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 15.03 per share. | 30 Mar 2021 | 11,989 | 1,256,224 | - | 15.0 | 180,195 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 14.64 per share. | 30 Mar 2021 | 8,330 | 1,247,894 | - | 14.6 | 121,951 | Common Stock |
| Jean-Francois Formela | Director | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 30 Mar 2021 | 5,959 | 1,241,935 | - | 14 | 83,426 | Common Stock |
| Jean-Francois Formela | Director | 30 Mar 2021 | 1,099,118 | 1,268,213 | - | - | Common Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 983,054 | 0 | - | - | Series B Preferred Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 653,277 | 0 | - | - | Series A-1 Preferred Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 2,411,260 | 0 | - | - | Series A-1 Preferred Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 551,259 | 0 | - | - | Series A Preferred Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 2,034,708 | 0 | - | - | Series A Preferred Stock | ||
| David P. Bonita | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 8,938,148 | 8,938,148 | - | - | Series B Preferred Stock | |
| Otello Stampacchia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 12,870,933 | 12,870,933 | - | - | Series B Preferred Stock | |
| Otello Stampacchia | Director | 30 Mar 2021 | 1,799,123 | 1,799,123 | - | - | Common Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 5,429,023 | 5,429,023 | - | - | Non-Voting Common Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 1,470,872 | 1,470,872 | - | - | Common Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 42,614 | 42,614 | - | - | Common Stock | ||
| David P. Bonita | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 30 Mar 2021 | 375,000 | 1,845,872 | - | 16 | 6,000,000 | Common Stock |
| David P. Bonita | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 30 Mar 2021 | 48,400 | 91,014 | - | 16 | 774,400 | Common Stock |
| David P. Bonita | Director | 30 Mar 2021 | 157,288 | 157,288 | - | - | Non-Voting Common Stock | ||
| Otello Stampacchia | Director | 30 Mar 2021 | 12,870,933 | 0 | - | - | Series B Preferred Stock | ||
| David P. Bonita | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 1,430,103 | 1,430,103 | - | - | Series B Preferred Stock | |
| David P. Bonita | Director | 30 Mar 2021 | 42,614 | 0 | - | - | Series B Preferred Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 157,288 | 0 | - | - | Series B Preferred Stock | ||
| David P. Bonita | Director | 30 Mar 2021 | 266,337 | 0 | - | - | Series B Preferred Stock | ||
| Otello Stampacchia | Director | Grant, award, or other acquisition of securities at price $ 16.00 per share. | 30 Mar 2021 | 450,000 | 2,249,123 | - | 16 | 7,200,000 | Common Stock |
| Jean-Francois Formela | Director | 30 Mar 2021 | 2,901,609 | 2,901,609 | - | - | Common Stock | ||
| Jean-Francois Formela | Director | 30 Mar 2021 | 749,634 | 749,634 | - | - | Common Stock | ||
| Jean-Francois Formela | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2021 | 5,362,888 | 5,362,888 | - | - | Series B Preferred Stock |